Search Results

You are looking at 31 - 40 of 61 items for :

  • "fertility preservation" x
Clear All
Full access

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns and Miranda Hughes

cell tumors, borderline epithelial tumors, unilateral stage I epithelial ovarian tumors, or unilateral stage I sex cord-stromal tumors. 116 , 117 , 120 , 137 – 140 Patients who do not desire fertility preservation; those who have a clinical stage IB

Full access

Kari E. Hacker, Shitanshu Uppal and Carolyn Johnston

invasive implants are present, especially if they are not surgically debulked ( Figure 1 ). Management Borderline Tumors BOTs are frequently diagnosed in women of childbearing age who desire fertility preservation. In studies assessing the

Full access

ovary) for women who wish to maintain their fertility, and standard ovarian cancer debulking surgery is recommended for those not concerned about fertility preservation. On the contrary, in women diagnosed with stage II, III, or IV epithelial ovarian

Full access

physicians need to better address intimacy, fertility preservation, and overall sexuality,” said Ronit Yarden, PhD, MHSA, Senior Director of Medical Affairs, Colorectal Cancer Alliance. “Treatments for colorectal cancer often come with debilitating side

Full access

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead and Rashmi Kumar

cancer treatment should undergo consultation with a physician with expertise in fertility before initiation of chemotherapy. 47 , 50 Multiple factors must be considered when making a decision about fertility preservation, including patient preference

Full access

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Nicole R. McMillian and Jillian Scavone

typically allows for fertility preservation. 4 , 5 Types of GTD HM occurs as a result of abnormal fertilization and is characterized as complete or partial based on differences in morphology, karyotype, and malignant potential. Most complete moles (80

Full access

Intervention to Improve Decision Satisfaction and Decrease Regret in Women Considering Fertility Preservation Terri Lynn Woodard, MD; Laura Covarrubias, MSPH; Andrea Michele Bradford, PhD; and Leslie R. Schover, PhD From The University of Texas MD Anderson

Full access

Terrell Johnson, Lindsey A.M. Bandini, Kara Martin, Lee Jones, Jennifer Carlson, Ronald S. Walters and Robert W. Carlson

-of-pocket costs for mature oocyte cryopreservation. 34 To resolve this oversight, Senator Lesser introduced Proposed Bill 5644 (PB 5644) in 2013, amending existing law to require fertility preservation in patients with cancer or anyone with a medical condition

Full access

Kevin M. Elias, Ross S. Berkowitz and Neil S. Horowitz

(>39 or <19 years) have been identified as risk factors for failure of second curettage to avoid the need for chemotherapy. 59 , 60 Role of Hysterectomy Women with FIGO stage I nonmetastatic GTN who do not desire fertility preservation may be treated

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass and Nicole R. McMillian

Premenopausal cancer survivors who have received chemotherapy may experience transient or permanent menopause. 14 – 16 If appropriate and desired, referral for fertility preservation should be considered before chemotherapy, because studies report that 33% to